Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/81727
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Palmer, D. | - |
dc.contributor.author | Sullivan, T. | - |
dc.contributor.author | Gold, M. | - |
dc.contributor.author | Prescott, S. | - |
dc.contributor.author | Heddle, R. | - |
dc.contributor.author | Gibson, R. | - |
dc.contributor.author | Makrides, M. | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Allergy, 2013; 68(11):1370-1376 | - |
dc.identifier.issn | 0105-4538 | - |
dc.identifier.issn | 1398-9995 | - |
dc.identifier.uri | http://hdl.handle.net/2440/81727 | - |
dc.description.abstract | <h4>Background</h4>Diets high in n-3 long chain polyunsaturated fatty acids (LCPUFA) may modulate the development of IgE-mediated allergic disease and have been proposed as a possible allergy prevention strategy. The aim of this study was to determine whether n-3 LCPUFA supplementation of pregnant women reduces IgE-mediated allergic disease in their children.<h4>Methods</h4>Follow-up of children (n = 706) at hereditary risk of allergic disease in the Docosahexaenoic Acid to Optimise Mother Infant Outcome randomized controlled trial. The intervention group (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily) from 21 weeks' gestation until birth; the control group (n = 338) received matched vegetable oil capsules without n-3 LCPUFA. The diagnosis of allergic disease was made during medical assessments at 1 and 3 years of age.<h4>Results</h4>No differences were seen in the overall percentage of children with IgE-mediated allergic disease in the first 3 years of life between the n-3 LCPUFA and control groups (64/368 (17.3%) vs 76/338 (22.6%); adjusted relative risk 0.78; 95% CI 0.58-1.06; P = 0.11). Eczema was the most common allergic disease; 13.8% of children in the n-3 LCPUFA group had eczema with sensitization compared with 19.0% in the control group (adjusted relative risk 0.75; 95% CI 0.53-1.05; P = 0.10).<h4>Conclusions</h4>Overall, n-3 LCPUFA supplementation during pregnancy did not significantly reduce IgE-associated allergic disease in the first 3 years of life. Further studies should examine whether the nonsignificant reductions in IgE-associated allergies are of clinical and public health significance. | - |
dc.description.statementofresponsibility | D. J. Palmer, T. Sullivan, M. S. Gold, S. L. Prescott, R. Heddle, R. A. Gibson & M. Makrides | - |
dc.language.iso | en | - |
dc.publisher | Munksgaard Int Publ Ltd | - |
dc.rights | © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd | - |
dc.source.uri | http://dx.doi.org/10.1111/all.12233 | - |
dc.subject | allergy prevention | - |
dc.subject | eczema | - |
dc.subject | fatty acids | - |
dc.subject | pregnancy | - |
dc.subject | randomized controlled trial | - |
dc.title | Randomized controlled trial of fish oil supplementation in pregnancy on childhood allergies | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1111/all.12233 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Gold, M. [0000-0003-1312-5331] | - |
dc.identifier.orcid | Gibson, R. [0000-0002-8750-525X] | - |
dc.identifier.orcid | Makrides, M. [0000-0003-3832-541X] | - |
Appears in Collections: | Aurora harvest 4 Paediatrics publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_81727.pdf | Submitted version | 148.58 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.